Clinical Pharmacokinetic Characteristics of Cebranopadol, a Novel First-in-Class Analgesic

Abstract

Cebranopadol formulated as an IR product can be used as a once-daily formulation; it reaches C _max after only 4-6 h, and has a long HVD and a low PTF. Therefore, from a PK perspective, cebranopadol is an attractive treatment option for patients with chronic pain.